View ValuationALPEK. de 将来の成長Future 基準チェック /36ALPEK. de利益と収益がそれぞれ年間96%と1.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に8.9% 97%なると予測されています。主要情報96.0%収益成長率97.03%EPS成長率Chemicals 収益成長65.5%収益成長率1.2%将来の株主資本利益率8.90%アナリストカバレッジGood最終更新日25 May 2026今後の成長に関する最新情報分析記事 • Jul 26Earnings Miss: ALPEK, S.A.B. de C.V. Missed EPS And Analysts Are Revising Their ForecastsShareholders might have noticed that ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) filed its second-quarter result this time...分析記事 • Apr 25Analysts Have Been Trimming Their ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Price Target After Its Latest ReportThe investors in ALPEK, S.A.B. de C.V. 's ( BMV:ALPEKA ) will be rubbing their hands together with glee today, after...Price Target Changed • Apr 24Price target decreased by 9.3% to Mex$15.79Down from Mex$17.42, the current price target is an average from 12 analysts. New target price is 54% above last closing price of Mex$10.27. Stock is down 19% over the past year. The company is forecast to post earnings per share of Mex$0.91 next year compared to a net loss per share of Mex$0.36 last year.Price Target Changed • Apr 01Price target decreased by 7.8% to Mex$17.67Down from Mex$19.17, the current price target is an average from 12 analysts. New target price is 75% above last closing price of Mex$10.07. Stock is down 21% over the past year. The company is forecast to post earnings per share of Mex$1.13 next year compared to a net loss per share of Mex$0.36 last year.Price Target Changed • Dec 15Price target decreased by 7.9% to Mex$18.92Down from Mex$20.54, the current price target is an average from 12 analysts. New target price is 38% above last closing price of Mex$13.73. Stock is up 3.5% over the past year. The company is forecast to post earnings per share of Mex$0.76 next year compared to a net loss per share of Mex$5.18 last year.分析記事 • Jul 27ALPEK, S.A.B. de C.V. Just Missed Earnings - But Analysts Have Updated Their ModelsThe analysts might have been a bit too bullish on ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), given that the company fell...すべての更新を表示Recent updatesBuy Or Sell Opportunity • May 07Now 21% undervaluedOver the last 90 days, the stock has risen 24% to Mex$12.26. The fair value is estimated to be Mex$15.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Apr 24First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: Mex$0.54 loss per share (down from Mex$0.081 profit in 1Q 2025). Revenue: Mex$29.8b (down 15% from 1Q 2025). Net loss: Mex$1.12b (down Mex$1.29b from profit in 1Q 2025). Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.Buy Or Sell Opportunity • Apr 02Now 23% undervaluedOver the last 90 days, the stock has risen 14% to Mex$10.91. The fair value is estimated to be Mex$14.10, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Mar 25ALPEK, S.A.B. de C.V. to Report Q1, 2026 Results on Apr 22, 2026ALPEK, S.A.B. de C.V. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026お知らせ • Feb 13ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 03, 2026ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 03, 2026. Location: 1111 gomez morin avenue, carrizalejo neighborhood, san pedro garza garcia, nuevo leon, monterrey MexicoReported Earnings • Feb 12Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: Mex$1.32 loss per share (further deteriorated from Mex$0.36 loss in FY 2024). Revenue: Mex$126.8b (down 7.7% from FY 2024). Net loss: Mex$2.77b (loss widened 263% from FY 2024). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to stay flat during the next 3 years compared to a 4.4% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.New Risk • Feb 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Mexican stocks, typically moving 5.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). Share price has been highly volatile over the past 3 months (5.6% average weekly change).分析記事 • Feb 06ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Price Is Out Of Tune With RevenuesWith a median price-to-sales (or "P/S") ratio of close to 0.5x in the Chemicals industry in Mexico, you could be...新しいナラティブ • Jan 25Tariffs And Footprint Optimization Will Support A Stronger Long Term Earnings MixCatalysts About ALPEK. de Alpek is a petrochemical company with core operations in polyester, plastics and chemicals, focused largely on the North American market.お知らせ • Jan 14ALPEK, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 10, 2026ALPEK, S.A.B. de C.V. announced that they will report Q4, 2025 results on Feb 10, 2026分析記事 • Jan 10Be Wary Of ALPEK. de (BMV:ALPEKA) And Its Returns On CapitalWhen researching a stock for investment, what can tell us that the company is in decline? Typically, we'll see the...New Risk • Dec 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Mexican stocks, typically moving 6.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). Share price has been highly volatile over the past 3 months (6.3% average weekly change).New Risk • Oct 24New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change).Reported Earnings • Oct 23Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: Mex$0.38 loss per share (down from Mex$0.23 profit in 3Q 2024). Revenue: Mex$31.1b (down 16% from 3Q 2024). Net loss: Mex$807.3m (down 267% from profit in 3Q 2024). Revenue missed analyst estimates by 9.7%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.分析記事 • Oct 17ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Stock Rockets 29% As Investors Are Less Pessimistic Than ExpectedALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) shares have had a really impressive month, gaining 29% after a shaky period...分析記事 • Oct 06Returns On Capital At ALPEK. de (BMV:ALPEKA) Have Hit The BrakesIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...お知らせ • Sep 26ALPEK, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 21, 2025ALPEK, S.A.B. de C.V. announced that they will report Q3, 2025 results on Oct 21, 2025New Risk • Sep 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.4x net interest cover). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 120% Minor Risk Share price has been volatile over the past 3 months (4.7% average weekly change).分析記事 • Jul 26Earnings Miss: ALPEK, S.A.B. de C.V. Missed EPS And Analysts Are Revising Their ForecastsShareholders might have noticed that ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) filed its second-quarter result this time...Reported Earnings • Jul 25Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: Mex$0.27 loss per share (down from Mex$0.10 profit in 2Q 2024). Revenue: Mex$32.8b (flat on 2Q 2024). Net loss: Mex$572.0m (down 365% from profit in 2Q 2024). Revenue missed analyst estimates by 5.2%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.お知らせ • Jun 24ALPEK, S.A.B. de C.V. to Report Q2, 2025 Results on Jul 22, 2025ALPEK, S.A.B. de C.V. announced that they will report Q2, 2025 results on Jul 22, 2025分析記事 • Apr 25Analysts Have Been Trimming Their ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Price Target After Its Latest ReportThe investors in ALPEK, S.A.B. de C.V. 's ( BMV:ALPEKA ) will be rubbing their hands together with glee today, after...Price Target Changed • Apr 24Price target decreased by 9.3% to Mex$15.79Down from Mex$17.42, the current price target is an average from 12 analysts. New target price is 54% above last closing price of Mex$10.27. Stock is down 19% over the past year. The company is forecast to post earnings per share of Mex$0.91 next year compared to a net loss per share of Mex$0.36 last year.Reported Earnings • Apr 23First quarter 2025 earnings released: EPS: Mex$0.081 (vs Mex$0.065 in 1Q 2024)First quarter 2025 results: EPS: Mex$0.081 (up from Mex$0.065 in 1Q 2024). Revenue: Mex$35.0b (up 8.3% from 1Q 2024). Net income: Mex$170.0m (up 24% from 1Q 2024). Profit margin: 0.5% (up from 0.4% in 1Q 2024). Revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.分析記事 • Apr 15ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Shares Slammed 27% But Getting In Cheap Might Be Difficult RegardlessUnfortunately for some shareholders, the ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) share price has dived 27% in the last...お知らせ • Apr 03ALPEK, S.A.B. de C.V. to Report Q1, 2025 Results on Apr 22, 2025ALPEK, S.A.B. de C.V. announced that they will report Q1, 2025 results on Apr 22, 2025Price Target Changed • Apr 01Price target decreased by 7.8% to Mex$17.67Down from Mex$19.17, the current price target is an average from 12 analysts. New target price is 75% above last closing price of Mex$10.07. Stock is down 21% over the past year. The company is forecast to post earnings per share of Mex$1.13 next year compared to a net loss per share of Mex$0.36 last year.分析記事 • Mar 13Here's Why ALPEK. de (BMV:ALPEKA) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Mar 05ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 20, 2025ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 20, 2025. Location: ave gomez morin 1111 south, carrizalejo neighborhood, san pedro garza garcia, nuevo leon, monterrey MexicoNew Risk • Feb 27New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. Cash payout ratio: 120% Dividend yield: 19% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.9x net interest cover). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 120% Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).New Risk • Feb 19New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.9x net interest cover). Minor Risk Paying a dividend despite being loss-making.分析記事 • Feb 18Unpleasant Surprises Could Be In Store For ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) SharesIt's not a stretch to say that ALPEK, S.A.B. de C.V.'s ( BMV:ALPEKA ) price-to-sales (or "P/S") ratio of 0.2x right now...お知らせ • Jan 31ALPEK, S.A.B. de C.V. to Report Q4, 2024 Results on Feb 18, 2025ALPEK, S.A.B. de C.V. announced that they will report Q4, 2024 results on Feb 18, 2025分析記事 • Jan 30Is ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Trading At A 48% Discount?Key Insights The projected fair value for ALPEK. de is Mex$27.84 based on 2 Stage Free Cash Flow to Equity ALPEK. de's...Price Target Changed • Dec 15Price target decreased by 7.9% to Mex$18.92Down from Mex$20.54, the current price target is an average from 12 analysts. New target price is 38% above last closing price of Mex$13.73. Stock is up 3.5% over the past year. The company is forecast to post earnings per share of Mex$0.76 next year compared to a net loss per share of Mex$5.18 last year.分析記事 • Dec 12Is ALPEK. de (BMV:ALPEKA) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (90% net debt to equity). Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (4.7% average weekly change).Reported Earnings • Oct 29Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2024 results: EPS: Mex$0.23 (up from Mex$0.21 loss in 3Q 2023). Revenue: Mex$37.2b (up 11% from 3Q 2023). Net income: Mex$483.0m (up Mex$922.8m from 3Q 2023). Profit margin: 1.3% (up from net loss in 3Q 2023). Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.お知らせ • Oct 15ALPEK, S.A.B. de C.V. to Report Q3, 2024 Results on Oct 28, 2024ALPEK, S.A.B. de C.V. announced that they will report Q3, 2024 results After-Market on Oct 28, 2024分析記事 • Oct 11Why We're Not Concerned About ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Share PriceWith a median price-to-sales (or "P/S") ratio of close to 0.6x in the Chemicals industry in Mexico, you could be...分析記事 • Sep 12Returns On Capital Signal Difficult Times Ahead For ALPEK. de (BMV:ALPEKA)When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...分析記事 • Aug 21Should You Investigate ALPEK, S.A.B. de C.V. (BMV:ALPEKA) At Mex$11.86?While ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) might not have the largest market cap around , it received a lot of...分析記事 • Jul 27ALPEK, S.A.B. de C.V. Just Missed Earnings - But Analysts Have Updated Their ModelsThe analysts might have been a bit too bullish on ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), given that the company fell...Reported Earnings • Jul 26Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: EPS: Mex$0.10 (down from Mex$0.26 in 2Q 2023). Revenue: Mex$33.0b (down 9.0% from 2Q 2023). Net income: Mex$216.0m (down 61% from 2Q 2023). Profit margin: 0.7% (down from 1.5% in 2Q 2023). Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 48%. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.お知らせ • Jul 10ALPEK, S.A.B. de C.V. to Report Q2, 2024 Results on Jul 24, 2024ALPEK, S.A.B. de C.V. announced that they will report Q2, 2024 results on Jul 24, 2024分析記事 • Jun 21A Look At The Intrinsic Value Of ALPEK, S.A.B. de C.V. (BMV:ALPEKA)Key Insights ALPEK. de's estimated fair value is Mex$12.39 based on 2 Stage Free Cash Flow to Equity ALPEK. de's...分析記事 • Jun 06Some Investors May Be Worried About ALPEK. de's (BMV:ALPEKA) Returns On CapitalWhen it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...Buy Or Sell Opportunity • Jun 06Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 24% to Mex$15.42. The fair value is estimated to be Mex$12.72, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.9% over the last 3 years. Meanwhile, the company became loss making.分析記事 • Apr 25Earnings Miss: ALPEK, S.A.B. de C.V. Missed EPS By 51% And Analysts Are Revising Their ForecastsIt's been a good week for ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) shareholders, because the company has just released its...Reported Earnings • Apr 24First quarter 2024 earnings released: EPS: Mex$0.065 (vs Mex$0.043 loss in 1Q 2023)First quarter 2024 results: EPS: Mex$0.065 (up from Mex$0.043 loss in 1Q 2023). Revenue: Mex$32.3b (down 16% from 1Q 2023). Net income: Mex$137.0m (up Mex$228.4m from 1Q 2023). Profit margin: 0.4% (up from net loss in 1Q 2023). Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.分析記事 • Apr 13What ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) P/S Is Not Telling YouThere wouldn't be many who think ALPEK, S.A.B. de C.V.'s ( BMV:ALPEKA ) price-to-sales (or "P/S") ratio of 0.2x is...お知らせ • Apr 09ALPEK, S.A.B. de C.V. to Report Q1, 2024 Results on Apr 23, 2024ALPEK, S.A.B. de C.V. announced that they will report Q1, 2024 results on Apr 23, 2024Buy Or Sell Opportunity • Apr 06Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 9.2% to Mex$13.22. The fair value is estimated to be Mex$10.99, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.分析記事 • Mar 26At Mex$12.61, Is ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Worth Looking At Closely?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), is not the largest company out there, but it saw a double-digit share price rise...分析記事 • Mar 08ALPEK. de (BMV:ALPEKA) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Feb 23New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risk Dividend is not well covered by earnings (371% payout ratio).お知らせ • Feb 16ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 06, 2024ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 06, 2024, at 10:15 Central Standard Time. Location: Avenida Gómez Morín No. 1111 Sur, Colonia Carrizalejo, San Pedro Garza García, Nuevo León Nuevo Leon Mexico Agenda: To consider the Presentation and, as the case may be, approval of the reports referred to in Article 28, section IV, of the Mexican Securities Market Law, relating to the fiscal year 2023; to Proposal on the allocation of the income statement for the fiscal year 2023, which includes the determination of the maximum amount of funds that may be used to purchase the Company’s own stock; to Election of the members of the Board of Directors, as well as the Chairman of the Audit and Corporate Governance Committee; determination of their compensation and related agreements; to Appointment of delegates; to Reading and, as the case may be, approval of the Minutes of the Meeting; and to consider other matters if any.お知らせ • Jan 31ALPEK, S.A.B. de C.V. to Report Q4, 2023 Results on Feb 20, 2024ALPEK, S.A.B. de C.V. announced that they will report Q4, 2023 results on Feb 20, 2024分析記事 • Jan 22A Look At The Intrinsic Value Of ALPEK, S.A.B. de C.V. (BMV:ALPEKA)Key Insights ALPEK. de's estimated fair value is Mex$12.26 based on 2 Stage Free Cash Flow to Equity ALPEK. de's...分析記事 • Jan 04Investor Optimism Abounds ALPEK, S.A.B. de C.V. (BMV:ALPEKA) But Growth Is LackingThere wouldn't be many who think ALPEK, S.A.B. de C.V.'s ( BMV:ALPEKA ) price-to-sales (or "P/S") ratio of 0.2x is...分析記事 • Dec 14Is There Now An Opportunity In ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), might not be a large cap stock, but it led the BMV gainers with a relatively...Major Estimate Revision • Nov 29Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$0.725 to Mex$0.634 per share. Revenue forecast steady at Mex$142.3b. Net income forecast to grow 392% next year vs 54% growth forecast for Chemicals industry in Mexico. Consensus price target of Mex$22.98 unchanged from last update. Share price was steady at Mex$13.53 over the past week.分析記事 • Nov 24ALPEK. de (BMV:ALPEKA) Use Of Debt Could Be Considered RiskyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Major Estimate Revision • Nov 10Consensus EPS estimates fall by 20%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$0.753 to Mex$0.603 per share. Revenue forecast steady at Mex$143.2b. Net income forecast to grow 455% next year vs 32% growth forecast for Chemicals industry in Mexico. Consensus price target broadly unchanged at Mex$22.80. Share price was steady at Mex$13.01 over the past week.Major Estimate Revision • Oct 30Consensus EPS estimates fall by 50%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$1.50 to Mex$0.753 per share. Revenue forecast steady at Mex$144.9b. Net income forecast to grow 554% next year vs 32% growth forecast for Chemicals industry in Mexico. Consensus price target down from Mex$25.47 to Mex$23.53. Share price fell 27% to Mex$10.12 over the past week.Valuation Update With 7 Day Price Move • Oct 30Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to Mex$10.12, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 14x in the Chemicals industry globally. Total loss to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$16.42 per share.New Risk • Oct 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (57% net debt to equity). Dividend is not well covered by earnings (368% payout ratio). Share price has been volatile over the past 3 months (4.7% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin).Price Target Changed • Oct 25Price target decreased by 7.6% to Mex$23.53Down from Mex$25.47, the current price target is an average from 11 analysts. New target price is 89% above last closing price of Mex$12.47. Stock is down 54% over the past year. The company is forecast to post earnings per share of Mex$0.75 for next year compared to Mex$6.52 last year.Reported Earnings • Oct 24Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: Mex$0.21 loss per share (down from Mex$1.07 profit in 3Q 2022). Revenue: Mex$33.4b (down 44% from 3Q 2022). Net loss: Mex$439.0m (down 120% from profit in 3Q 2022). Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 1.9% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • Oct 10ALPEK, S.A.B. de C.V. to Report Q3, 2023 Results on Oct 23, 2023ALPEK, S.A.B. de C.V. announced that they will report Q3, 2023 results on Oct 23, 2023Major Estimate Revision • Sep 04Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from Mex$143.5b to Mex$142.0b. EPS estimate also fell from Mex$1.59 per share to Mex$1.42 per share. Net income forecast to grow 18% next year vs 31% growth forecast for Chemicals industry in Mexico. Consensus price target broadly unchanged at Mex$26.11. Share price was steady at Mex$16.53 over the past week.分析記事 • Sep 02Is Now The Time To Look At Buying ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?While ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) might not be the most widely known stock at the moment, it received a lot of...New Risk • Aug 14New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.9% Last year net profit margin: 7.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (63% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (1.9% net profit margin).Major Estimate Revision • Aug 13Consensus EPS estimates fall by 10%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$1.77 to Mex$1.59 per share. Revenue forecast steady at Mex$145.2b. Net income forecast to grow 27% next year vs 25% growth forecast for Chemicals industry in Mexico. Consensus price target broadly unchanged at Mex$26.36. Share price was steady at Mex$17.05 over the past week.Price Target Changed • Aug 03Price target decreased by 8.0% to Mex$26.44Down from Mex$28.75, the current price target is an average from 14 analysts. New target price is 51% above last closing price of Mex$17.48. Stock is down 35% over the past year. The company is forecast to post earnings per share of Mex$1.77 for next year compared to Mex$6.52 last year.Major Estimate Revision • Jul 28Consensus EPS estimates increase by 13%, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from Mex$157.3b to Mex$150.2b. EPS estimate rose from Mex$2.32 to Mex$2.63. Net income forecast to shrink 46% next year vs 23% growth forecast for Chemicals industry in Mexico . Consensus price target down from Mex$29.68 to Mex$28.06. Share price was steady at Mex$17.29 over the past week.Reported Earnings • Jul 28Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: Mex$36.3b (down 36% from 2Q 2022). Net income: Mex$555.0m (down 91% from 2Q 2022). Profit margin: 1.5% (down from 11% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to decline by 2.1% p.a. on average during the next 3 years, while revenues in the Chemicals industry in South America are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.分析記事 • Jul 16ALPEK. de (BMV:ALPEKA) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...お知らせ • Jul 07ALPEK, S.A.B. de C.V. to Report Q2, 2023 Results on Jul 26, 2023ALPEK, S.A.B. de C.V. announced that they will report Q2, 2023 results at 11:30 AM, Central Standard Time on Jul 26, 2023分析記事 • Jun 27ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Intrinsic Value Is Potentially 91% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, ALPEK. de fair value estimate is Mex$32.21 Current share price...Major Estimate Revision • May 10Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$2.73 to Mex$2.42. Revenue forecast unchanged from Mex$163.8b at last update. Net income forecast to shrink 33% next year vs 31% growth forecast for Chemicals industry in Mexico . Consensus price target reaffirmed at Mex$30.61. Share price was steady at Mex$19.28 over the past week.分析記事 • Apr 30The ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Analysts Have Been Trimming Their Sales ForecastsOne thing we could say about the analysts on ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) - they aren't optimistic, having just...Reported Earnings • Apr 28First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: Mex$0.043 loss per share (down from Mex$2.23 profit in 1Q 2022). Revenue: Mex$38.6b (down 19% from 1Q 2022). Net loss: Mex$91.0m (down 102% from profit in 1Q 2022). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, while revenues in the Chemicals industry in South America are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.分析記事 • Apr 20When Should You Buy ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?While ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) might not be the most widely known stock at the moment, it received a lot of...Major Estimate Revision • Mar 29Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$3.29 to Mex$2.86 per share. Revenue forecast steady at Mex$172.8b. Net income forecast to shrink 55% next year vs 20% growth forecast for Chemicals industry in Mexico . Consensus price target down from Mex$31.96 to Mex$31.32. Share price fell 4.7% to Mex$20.68 over the past week.分析記事 • Mar 28An Intrinsic Calculation For ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Suggests It's 34% UndervaluedKey Insights The projected fair value for ALPEK. de is Mex$30.88 based on 2 Stage Free Cash Flow to Equity ALPEK. de is...分析記事 • Feb 25These Analysts Think ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Sales Are Under ThreatMarket forces rained on the parade of ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) shareholders today, when the analysts...Major Estimate Revision • Feb 24Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from Mex$194.4b to Mex$174.4b. EPS estimate fell from Mex$4.14 to Mex$3.92 per share. Net income forecast to shrink 38% next year vs 6.5% decline forecast for Chemicals industry in Mexico. Consensus price target down from Mex$35.20 to Mex$33.24. Share price fell 6.1% to Mex$22.24 over the past week.分析記事 • Feb 23Is ALPEK. de (BMV:ALPEKA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Buying Opportunity • Feb 18Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be Mex$30.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 39%. For the next 3 years, revenue is forecast to decline by 7.4% per annum. Earnings is also forecast to decline by 29% per annum over the same time period.Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to Mex$23.68, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 7x in the Chemicals industry in South America. Total returns to shareholders of 101% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$23.26 per share.お知らせ • Feb 01ALPEK, S.A.B. de C.V. to Report Q4, 2022 Results on Feb 15, 2023ALPEK, S.A.B. de C.V. announced that they will report Q4, 2022 results on Feb 15, 2023分析記事 • Jan 07Is It Too Late To Consider Buying ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), is not the largest company out there, but it saw a decent share price growth in...分析記事 • Dec 22Estimating The Intrinsic Value Of ALPEK, S.A.B. de C.V. (BMV:ALPEKA)Key Insights ALPEK. de's estimated fair value is Mex$30.5 based on 2 Stage Free Cash Flow to Equity Current share price...Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 8 highly experienced directors. Independent Director Jaime Zabludovsky Kuper was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 22Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2022 results: EPS: Mex$1.07 (up from Mex$1.05 in 3Q 2021). Revenue: Mex$59.8b (up 44% from 3Q 2021). Net income: Mex$2.25b (up 1.2% from 3Q 2021). Profit margin: 3.8% (down from 5.3% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) missed analyst estimates by 37%. Revenue is expected to fall by 4.7% p.a. on average during the next 3 years compared to a 1.9% decline forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.分析記事 • Sep 24At Mex$26.92, Is ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Worth Looking At Closely?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), is not the largest company out there, but it saw significant share price movement...分析記事 • Aug 30We Think ALPEK. de (BMV:ALPEKA) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Buying Opportunity • Aug 05Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 2.1%. The fair value is estimated to be Mex$34.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to decline by 4.4% per annum. Earnings is also forecast to decline by 37% per annum over the same time period.業績と収益の成長予測BMV:ALPEK A - アナリストの将来予測と過去の財務データ ( )MXN Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028127,7473,4034,4416,185712/31/2027127,3082,2474,3683,8291012/31/2026127,6259647,2246,820103/31/2026121,579-4,0626,3148,892N/A12/31/2025126,840-2,7745,1757,615N/A9/30/2025133,745-2,8103,7346,212N/A6/30/2025139,829-1,5194,2186,565N/A3/31/2025140,082-7325,8817,941N/A12/31/2024137,409-7654,2246,258N/A9/30/2024132,434-10,1036,2098,372N/A6/30/2024128,647-11,0268,38810,717N/A3/31/2024131,934-10,68610,85213,447N/A12/31/2023138,159-10,91412,48315,024N/A9/30/2023156,68376715,20217,496N/A6/30/2023183,0653,45311,98214,816N/A3/31/2023203,1338,9559,70412,462N/A12/31/2022212,43513,74412,13115,210N/A9/30/2022208,68913,60212,68315,800N/A6/30/2022190,59113,57611,29513,880N/A3/31/2022171,27110,00110,67215,314N/A12/31/2021156,2247,7568,79413,230N/A9/30/2021140,2689,1755,2789,901N/A6/30/2021127,9278,3929,87414,529N/A3/31/2021118,2976,0288,28010,941N/A12/31/2020113,9893,1239,34611,934N/A9/30/2020112,4135,1518,18010,785N/A6/30/2020112,6624,6916,0268,838N/A3/31/2020116,6405,6358,29511,168N/A12/31/2019119,6856,605N/A10,001N/A9/30/2019127,35410,373N/A10,296N/A6/30/2019134,62710,913N/A9,149N/A3/31/2019137,34512,601N/A8,231N/A12/31/2018134,52313,633N/A8,261N/A9/30/2018124,7315,240N/A8,372N/A6/30/2018111,272-3,406N/A6,457N/A3/31/2018101,404-5,707N/A7,484N/A12/31/201798,998-5,487N/A7,225N/A9/30/201797,416-4,366N/A6,004N/A6/30/201797,1733,697N/A8,961N/A3/31/201795,2404,112N/A7,739N/A12/31/201690,1923,625N/A6,019N/A9/30/201687,1743,558N/A6,724N/A6/30/201686,1033,248N/A6,949N/A3/31/201685,1613,654N/A6,940N/A12/31/201583,5902,748N/A8,178N/A9/30/201585,9811,844N/A9,631N/A6/30/201585,3311,615N/A7,471N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ALPEK Aは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 9% ) よりも高い成長率であると考えられます。収益対市場: ALPEK A今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: ALPEK A今後 3 年以内に収益を上げることが予想されます。収益対市場: ALPEK Aの収益 ( 1.2% ) MX市場 ( 6.2% ) よりも低い成長が予測されています。高い収益成長: ALPEK Aの収益 ( 1.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ALPEK Aの 自己資本利益率 は、3年後には低くなると予測されています ( 8.9 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 23:42終値2026/05/26 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ALPEK, S.A.B. de C.V. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Gilberto GarciaBarclaysPablo Monsivais MendozaBarclaysLeonardo MarcondesBofA Global Research13 その他のアナリストを表示
分析記事 • Jul 26Earnings Miss: ALPEK, S.A.B. de C.V. Missed EPS And Analysts Are Revising Their ForecastsShareholders might have noticed that ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) filed its second-quarter result this time...
分析記事 • Apr 25Analysts Have Been Trimming Their ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Price Target After Its Latest ReportThe investors in ALPEK, S.A.B. de C.V. 's ( BMV:ALPEKA ) will be rubbing their hands together with glee today, after...
Price Target Changed • Apr 24Price target decreased by 9.3% to Mex$15.79Down from Mex$17.42, the current price target is an average from 12 analysts. New target price is 54% above last closing price of Mex$10.27. Stock is down 19% over the past year. The company is forecast to post earnings per share of Mex$0.91 next year compared to a net loss per share of Mex$0.36 last year.
Price Target Changed • Apr 01Price target decreased by 7.8% to Mex$17.67Down from Mex$19.17, the current price target is an average from 12 analysts. New target price is 75% above last closing price of Mex$10.07. Stock is down 21% over the past year. The company is forecast to post earnings per share of Mex$1.13 next year compared to a net loss per share of Mex$0.36 last year.
Price Target Changed • Dec 15Price target decreased by 7.9% to Mex$18.92Down from Mex$20.54, the current price target is an average from 12 analysts. New target price is 38% above last closing price of Mex$13.73. Stock is up 3.5% over the past year. The company is forecast to post earnings per share of Mex$0.76 next year compared to a net loss per share of Mex$5.18 last year.
分析記事 • Jul 27ALPEK, S.A.B. de C.V. Just Missed Earnings - But Analysts Have Updated Their ModelsThe analysts might have been a bit too bullish on ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), given that the company fell...
Buy Or Sell Opportunity • May 07Now 21% undervaluedOver the last 90 days, the stock has risen 24% to Mex$12.26. The fair value is estimated to be Mex$15.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Apr 24First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: Mex$0.54 loss per share (down from Mex$0.081 profit in 1Q 2025). Revenue: Mex$29.8b (down 15% from 1Q 2025). Net loss: Mex$1.12b (down Mex$1.29b from profit in 1Q 2025). Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
Buy Or Sell Opportunity • Apr 02Now 23% undervaluedOver the last 90 days, the stock has risen 14% to Mex$10.91. The fair value is estimated to be Mex$14.10, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Mar 25ALPEK, S.A.B. de C.V. to Report Q1, 2026 Results on Apr 22, 2026ALPEK, S.A.B. de C.V. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026
お知らせ • Feb 13ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 03, 2026ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 03, 2026. Location: 1111 gomez morin avenue, carrizalejo neighborhood, san pedro garza garcia, nuevo leon, monterrey Mexico
Reported Earnings • Feb 12Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: Mex$1.32 loss per share (further deteriorated from Mex$0.36 loss in FY 2024). Revenue: Mex$126.8b (down 7.7% from FY 2024). Net loss: Mex$2.77b (loss widened 263% from FY 2024). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to stay flat during the next 3 years compared to a 4.4% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.
New Risk • Feb 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Mexican stocks, typically moving 5.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). Share price has been highly volatile over the past 3 months (5.6% average weekly change).
分析記事 • Feb 06ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Price Is Out Of Tune With RevenuesWith a median price-to-sales (or "P/S") ratio of close to 0.5x in the Chemicals industry in Mexico, you could be...
新しいナラティブ • Jan 25Tariffs And Footprint Optimization Will Support A Stronger Long Term Earnings MixCatalysts About ALPEK. de Alpek is a petrochemical company with core operations in polyester, plastics and chemicals, focused largely on the North American market.
お知らせ • Jan 14ALPEK, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 10, 2026ALPEK, S.A.B. de C.V. announced that they will report Q4, 2025 results on Feb 10, 2026
分析記事 • Jan 10Be Wary Of ALPEK. de (BMV:ALPEKA) And Its Returns On CapitalWhen researching a stock for investment, what can tell us that the company is in decline? Typically, we'll see the...
New Risk • Dec 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Mexican stocks, typically moving 6.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). Share price has been highly volatile over the past 3 months (6.3% average weekly change).
New Risk • Oct 24New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change).
Reported Earnings • Oct 23Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: Mex$0.38 loss per share (down from Mex$0.23 profit in 3Q 2024). Revenue: Mex$31.1b (down 16% from 3Q 2024). Net loss: Mex$807.3m (down 267% from profit in 3Q 2024). Revenue missed analyst estimates by 9.7%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.
分析記事 • Oct 17ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Stock Rockets 29% As Investors Are Less Pessimistic Than ExpectedALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) shares have had a really impressive month, gaining 29% after a shaky period...
分析記事 • Oct 06Returns On Capital At ALPEK. de (BMV:ALPEKA) Have Hit The BrakesIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
お知らせ • Sep 26ALPEK, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 21, 2025ALPEK, S.A.B. de C.V. announced that they will report Q3, 2025 results on Oct 21, 2025
New Risk • Sep 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.4x net interest cover). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 120% Minor Risk Share price has been volatile over the past 3 months (4.7% average weekly change).
分析記事 • Jul 26Earnings Miss: ALPEK, S.A.B. de C.V. Missed EPS And Analysts Are Revising Their ForecastsShareholders might have noticed that ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) filed its second-quarter result this time...
Reported Earnings • Jul 25Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: Mex$0.27 loss per share (down from Mex$0.10 profit in 2Q 2024). Revenue: Mex$32.8b (flat on 2Q 2024). Net loss: Mex$572.0m (down 365% from profit in 2Q 2024). Revenue missed analyst estimates by 5.2%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.
お知らせ • Jun 24ALPEK, S.A.B. de C.V. to Report Q2, 2025 Results on Jul 22, 2025ALPEK, S.A.B. de C.V. announced that they will report Q2, 2025 results on Jul 22, 2025
分析記事 • Apr 25Analysts Have Been Trimming Their ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Price Target After Its Latest ReportThe investors in ALPEK, S.A.B. de C.V. 's ( BMV:ALPEKA ) will be rubbing their hands together with glee today, after...
Price Target Changed • Apr 24Price target decreased by 9.3% to Mex$15.79Down from Mex$17.42, the current price target is an average from 12 analysts. New target price is 54% above last closing price of Mex$10.27. Stock is down 19% over the past year. The company is forecast to post earnings per share of Mex$0.91 next year compared to a net loss per share of Mex$0.36 last year.
Reported Earnings • Apr 23First quarter 2025 earnings released: EPS: Mex$0.081 (vs Mex$0.065 in 1Q 2024)First quarter 2025 results: EPS: Mex$0.081 (up from Mex$0.065 in 1Q 2024). Revenue: Mex$35.0b (up 8.3% from 1Q 2024). Net income: Mex$170.0m (up 24% from 1Q 2024). Profit margin: 0.5% (up from 0.4% in 1Q 2024). Revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.
分析記事 • Apr 15ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Shares Slammed 27% But Getting In Cheap Might Be Difficult RegardlessUnfortunately for some shareholders, the ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) share price has dived 27% in the last...
お知らせ • Apr 03ALPEK, S.A.B. de C.V. to Report Q1, 2025 Results on Apr 22, 2025ALPEK, S.A.B. de C.V. announced that they will report Q1, 2025 results on Apr 22, 2025
Price Target Changed • Apr 01Price target decreased by 7.8% to Mex$17.67Down from Mex$19.17, the current price target is an average from 12 analysts. New target price is 75% above last closing price of Mex$10.07. Stock is down 21% over the past year. The company is forecast to post earnings per share of Mex$1.13 next year compared to a net loss per share of Mex$0.36 last year.
分析記事 • Mar 13Here's Why ALPEK. de (BMV:ALPEKA) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Mar 05ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 20, 2025ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 20, 2025. Location: ave gomez morin 1111 south, carrizalejo neighborhood, san pedro garza garcia, nuevo leon, monterrey Mexico
New Risk • Feb 27New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. Cash payout ratio: 120% Dividend yield: 19% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.9x net interest cover). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 120% Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).
New Risk • Feb 19New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.9x net interest cover). Minor Risk Paying a dividend despite being loss-making.
分析記事 • Feb 18Unpleasant Surprises Could Be In Store For ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) SharesIt's not a stretch to say that ALPEK, S.A.B. de C.V.'s ( BMV:ALPEKA ) price-to-sales (or "P/S") ratio of 0.2x right now...
お知らせ • Jan 31ALPEK, S.A.B. de C.V. to Report Q4, 2024 Results on Feb 18, 2025ALPEK, S.A.B. de C.V. announced that they will report Q4, 2024 results on Feb 18, 2025
分析記事 • Jan 30Is ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Trading At A 48% Discount?Key Insights The projected fair value for ALPEK. de is Mex$27.84 based on 2 Stage Free Cash Flow to Equity ALPEK. de's...
Price Target Changed • Dec 15Price target decreased by 7.9% to Mex$18.92Down from Mex$20.54, the current price target is an average from 12 analysts. New target price is 38% above last closing price of Mex$13.73. Stock is up 3.5% over the past year. The company is forecast to post earnings per share of Mex$0.76 next year compared to a net loss per share of Mex$5.18 last year.
分析記事 • Dec 12Is ALPEK. de (BMV:ALPEKA) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (90% net debt to equity). Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (4.7% average weekly change).
Reported Earnings • Oct 29Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2024 results: EPS: Mex$0.23 (up from Mex$0.21 loss in 3Q 2023). Revenue: Mex$37.2b (up 11% from 3Q 2023). Net income: Mex$483.0m (up Mex$922.8m from 3Q 2023). Profit margin: 1.3% (up from net loss in 3Q 2023). Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
お知らせ • Oct 15ALPEK, S.A.B. de C.V. to Report Q3, 2024 Results on Oct 28, 2024ALPEK, S.A.B. de C.V. announced that they will report Q3, 2024 results After-Market on Oct 28, 2024
分析記事 • Oct 11Why We're Not Concerned About ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Share PriceWith a median price-to-sales (or "P/S") ratio of close to 0.6x in the Chemicals industry in Mexico, you could be...
分析記事 • Sep 12Returns On Capital Signal Difficult Times Ahead For ALPEK. de (BMV:ALPEKA)When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...
分析記事 • Aug 21Should You Investigate ALPEK, S.A.B. de C.V. (BMV:ALPEKA) At Mex$11.86?While ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) might not have the largest market cap around , it received a lot of...
分析記事 • Jul 27ALPEK, S.A.B. de C.V. Just Missed Earnings - But Analysts Have Updated Their ModelsThe analysts might have been a bit too bullish on ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), given that the company fell...
Reported Earnings • Jul 26Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: EPS: Mex$0.10 (down from Mex$0.26 in 2Q 2023). Revenue: Mex$33.0b (down 9.0% from 2Q 2023). Net income: Mex$216.0m (down 61% from 2Q 2023). Profit margin: 0.7% (down from 1.5% in 2Q 2023). Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 48%. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 10ALPEK, S.A.B. de C.V. to Report Q2, 2024 Results on Jul 24, 2024ALPEK, S.A.B. de C.V. announced that they will report Q2, 2024 results on Jul 24, 2024
分析記事 • Jun 21A Look At The Intrinsic Value Of ALPEK, S.A.B. de C.V. (BMV:ALPEKA)Key Insights ALPEK. de's estimated fair value is Mex$12.39 based on 2 Stage Free Cash Flow to Equity ALPEK. de's...
分析記事 • Jun 06Some Investors May Be Worried About ALPEK. de's (BMV:ALPEKA) Returns On CapitalWhen it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
Buy Or Sell Opportunity • Jun 06Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 24% to Mex$15.42. The fair value is estimated to be Mex$12.72, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.9% over the last 3 years. Meanwhile, the company became loss making.
分析記事 • Apr 25Earnings Miss: ALPEK, S.A.B. de C.V. Missed EPS By 51% And Analysts Are Revising Their ForecastsIt's been a good week for ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) shareholders, because the company has just released its...
Reported Earnings • Apr 24First quarter 2024 earnings released: EPS: Mex$0.065 (vs Mex$0.043 loss in 1Q 2023)First quarter 2024 results: EPS: Mex$0.065 (up from Mex$0.043 loss in 1Q 2023). Revenue: Mex$32.3b (down 16% from 1Q 2023). Net income: Mex$137.0m (up Mex$228.4m from 1Q 2023). Profit margin: 0.4% (up from net loss in 1Q 2023). Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.
分析記事 • Apr 13What ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) P/S Is Not Telling YouThere wouldn't be many who think ALPEK, S.A.B. de C.V.'s ( BMV:ALPEKA ) price-to-sales (or "P/S") ratio of 0.2x is...
お知らせ • Apr 09ALPEK, S.A.B. de C.V. to Report Q1, 2024 Results on Apr 23, 2024ALPEK, S.A.B. de C.V. announced that they will report Q1, 2024 results on Apr 23, 2024
Buy Or Sell Opportunity • Apr 06Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 9.2% to Mex$13.22. The fair value is estimated to be Mex$10.99, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.
分析記事 • Mar 26At Mex$12.61, Is ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Worth Looking At Closely?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), is not the largest company out there, but it saw a double-digit share price rise...
分析記事 • Mar 08ALPEK. de (BMV:ALPEKA) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Feb 23New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risk Dividend is not well covered by earnings (371% payout ratio).
お知らせ • Feb 16ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 06, 2024ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 06, 2024, at 10:15 Central Standard Time. Location: Avenida Gómez Morín No. 1111 Sur, Colonia Carrizalejo, San Pedro Garza García, Nuevo León Nuevo Leon Mexico Agenda: To consider the Presentation and, as the case may be, approval of the reports referred to in Article 28, section IV, of the Mexican Securities Market Law, relating to the fiscal year 2023; to Proposal on the allocation of the income statement for the fiscal year 2023, which includes the determination of the maximum amount of funds that may be used to purchase the Company’s own stock; to Election of the members of the Board of Directors, as well as the Chairman of the Audit and Corporate Governance Committee; determination of their compensation and related agreements; to Appointment of delegates; to Reading and, as the case may be, approval of the Minutes of the Meeting; and to consider other matters if any.
お知らせ • Jan 31ALPEK, S.A.B. de C.V. to Report Q4, 2023 Results on Feb 20, 2024ALPEK, S.A.B. de C.V. announced that they will report Q4, 2023 results on Feb 20, 2024
分析記事 • Jan 22A Look At The Intrinsic Value Of ALPEK, S.A.B. de C.V. (BMV:ALPEKA)Key Insights ALPEK. de's estimated fair value is Mex$12.26 based on 2 Stage Free Cash Flow to Equity ALPEK. de's...
分析記事 • Jan 04Investor Optimism Abounds ALPEK, S.A.B. de C.V. (BMV:ALPEKA) But Growth Is LackingThere wouldn't be many who think ALPEK, S.A.B. de C.V.'s ( BMV:ALPEKA ) price-to-sales (or "P/S") ratio of 0.2x is...
分析記事 • Dec 14Is There Now An Opportunity In ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), might not be a large cap stock, but it led the BMV gainers with a relatively...
Major Estimate Revision • Nov 29Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$0.725 to Mex$0.634 per share. Revenue forecast steady at Mex$142.3b. Net income forecast to grow 392% next year vs 54% growth forecast for Chemicals industry in Mexico. Consensus price target of Mex$22.98 unchanged from last update. Share price was steady at Mex$13.53 over the past week.
分析記事 • Nov 24ALPEK. de (BMV:ALPEKA) Use Of Debt Could Be Considered RiskyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Major Estimate Revision • Nov 10Consensus EPS estimates fall by 20%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$0.753 to Mex$0.603 per share. Revenue forecast steady at Mex$143.2b. Net income forecast to grow 455% next year vs 32% growth forecast for Chemicals industry in Mexico. Consensus price target broadly unchanged at Mex$22.80. Share price was steady at Mex$13.01 over the past week.
Major Estimate Revision • Oct 30Consensus EPS estimates fall by 50%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$1.50 to Mex$0.753 per share. Revenue forecast steady at Mex$144.9b. Net income forecast to grow 554% next year vs 32% growth forecast for Chemicals industry in Mexico. Consensus price target down from Mex$25.47 to Mex$23.53. Share price fell 27% to Mex$10.12 over the past week.
Valuation Update With 7 Day Price Move • Oct 30Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to Mex$10.12, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 14x in the Chemicals industry globally. Total loss to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$16.42 per share.
New Risk • Oct 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Mexican stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (57% net debt to equity). Dividend is not well covered by earnings (368% payout ratio). Share price has been volatile over the past 3 months (4.7% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin).
Price Target Changed • Oct 25Price target decreased by 7.6% to Mex$23.53Down from Mex$25.47, the current price target is an average from 11 analysts. New target price is 89% above last closing price of Mex$12.47. Stock is down 54% over the past year. The company is forecast to post earnings per share of Mex$0.75 for next year compared to Mex$6.52 last year.
Reported Earnings • Oct 24Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: Mex$0.21 loss per share (down from Mex$1.07 profit in 3Q 2022). Revenue: Mex$33.4b (down 44% from 3Q 2022). Net loss: Mex$439.0m (down 120% from profit in 3Q 2022). Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 1.9% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • Oct 10ALPEK, S.A.B. de C.V. to Report Q3, 2023 Results on Oct 23, 2023ALPEK, S.A.B. de C.V. announced that they will report Q3, 2023 results on Oct 23, 2023
Major Estimate Revision • Sep 04Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from Mex$143.5b to Mex$142.0b. EPS estimate also fell from Mex$1.59 per share to Mex$1.42 per share. Net income forecast to grow 18% next year vs 31% growth forecast for Chemicals industry in Mexico. Consensus price target broadly unchanged at Mex$26.11. Share price was steady at Mex$16.53 over the past week.
分析記事 • Sep 02Is Now The Time To Look At Buying ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?While ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) might not be the most widely known stock at the moment, it received a lot of...
New Risk • Aug 14New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.9% Last year net profit margin: 7.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (63% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (1.9% net profit margin).
Major Estimate Revision • Aug 13Consensus EPS estimates fall by 10%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$1.77 to Mex$1.59 per share. Revenue forecast steady at Mex$145.2b. Net income forecast to grow 27% next year vs 25% growth forecast for Chemicals industry in Mexico. Consensus price target broadly unchanged at Mex$26.36. Share price was steady at Mex$17.05 over the past week.
Price Target Changed • Aug 03Price target decreased by 8.0% to Mex$26.44Down from Mex$28.75, the current price target is an average from 14 analysts. New target price is 51% above last closing price of Mex$17.48. Stock is down 35% over the past year. The company is forecast to post earnings per share of Mex$1.77 for next year compared to Mex$6.52 last year.
Major Estimate Revision • Jul 28Consensus EPS estimates increase by 13%, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from Mex$157.3b to Mex$150.2b. EPS estimate rose from Mex$2.32 to Mex$2.63. Net income forecast to shrink 46% next year vs 23% growth forecast for Chemicals industry in Mexico . Consensus price target down from Mex$29.68 to Mex$28.06. Share price was steady at Mex$17.29 over the past week.
Reported Earnings • Jul 28Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: Mex$36.3b (down 36% from 2Q 2022). Net income: Mex$555.0m (down 91% from 2Q 2022). Profit margin: 1.5% (down from 11% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to decline by 2.1% p.a. on average during the next 3 years, while revenues in the Chemicals industry in South America are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
分析記事 • Jul 16ALPEK. de (BMV:ALPEKA) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
お知らせ • Jul 07ALPEK, S.A.B. de C.V. to Report Q2, 2023 Results on Jul 26, 2023ALPEK, S.A.B. de C.V. announced that they will report Q2, 2023 results at 11:30 AM, Central Standard Time on Jul 26, 2023
分析記事 • Jun 27ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Intrinsic Value Is Potentially 91% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, ALPEK. de fair value estimate is Mex$32.21 Current share price...
Major Estimate Revision • May 10Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$2.73 to Mex$2.42. Revenue forecast unchanged from Mex$163.8b at last update. Net income forecast to shrink 33% next year vs 31% growth forecast for Chemicals industry in Mexico . Consensus price target reaffirmed at Mex$30.61. Share price was steady at Mex$19.28 over the past week.
分析記事 • Apr 30The ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Analysts Have Been Trimming Their Sales ForecastsOne thing we could say about the analysts on ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) - they aren't optimistic, having just...
Reported Earnings • Apr 28First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: Mex$0.043 loss per share (down from Mex$2.23 profit in 1Q 2022). Revenue: Mex$38.6b (down 19% from 1Q 2022). Net loss: Mex$91.0m (down 102% from profit in 1Q 2022). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, while revenues in the Chemicals industry in South America are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
分析記事 • Apr 20When Should You Buy ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?While ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) might not be the most widely known stock at the moment, it received a lot of...
Major Estimate Revision • Mar 29Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from Mex$3.29 to Mex$2.86 per share. Revenue forecast steady at Mex$172.8b. Net income forecast to shrink 55% next year vs 20% growth forecast for Chemicals industry in Mexico . Consensus price target down from Mex$31.96 to Mex$31.32. Share price fell 4.7% to Mex$20.68 over the past week.
分析記事 • Mar 28An Intrinsic Calculation For ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Suggests It's 34% UndervaluedKey Insights The projected fair value for ALPEK. de is Mex$30.88 based on 2 Stage Free Cash Flow to Equity ALPEK. de is...
分析記事 • Feb 25These Analysts Think ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Sales Are Under ThreatMarket forces rained on the parade of ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ) shareholders today, when the analysts...
Major Estimate Revision • Feb 24Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from Mex$194.4b to Mex$174.4b. EPS estimate fell from Mex$4.14 to Mex$3.92 per share. Net income forecast to shrink 38% next year vs 6.5% decline forecast for Chemicals industry in Mexico. Consensus price target down from Mex$35.20 to Mex$33.24. Share price fell 6.1% to Mex$22.24 over the past week.
分析記事 • Feb 23Is ALPEK. de (BMV:ALPEKA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Buying Opportunity • Feb 18Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be Mex$30.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 39%. For the next 3 years, revenue is forecast to decline by 7.4% per annum. Earnings is also forecast to decline by 29% per annum over the same time period.
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to Mex$23.68, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 7x in the Chemicals industry in South America. Total returns to shareholders of 101% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$23.26 per share.
お知らせ • Feb 01ALPEK, S.A.B. de C.V. to Report Q4, 2022 Results on Feb 15, 2023ALPEK, S.A.B. de C.V. announced that they will report Q4, 2022 results on Feb 15, 2023
分析記事 • Jan 07Is It Too Late To Consider Buying ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), is not the largest company out there, but it saw a decent share price growth in...
分析記事 • Dec 22Estimating The Intrinsic Value Of ALPEK, S.A.B. de C.V. (BMV:ALPEKA)Key Insights ALPEK. de's estimated fair value is Mex$30.5 based on 2 Stage Free Cash Flow to Equity Current share price...
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 8 highly experienced directors. Independent Director Jaime Zabludovsky Kuper was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 22Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2022 results: EPS: Mex$1.07 (up from Mex$1.05 in 3Q 2021). Revenue: Mex$59.8b (up 44% from 3Q 2021). Net income: Mex$2.25b (up 1.2% from 3Q 2021). Profit margin: 3.8% (down from 5.3% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) missed analyst estimates by 37%. Revenue is expected to fall by 4.7% p.a. on average during the next 3 years compared to a 1.9% decline forecast for the Chemicals industry in South America. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
分析記事 • Sep 24At Mex$26.92, Is ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Worth Looking At Closely?ALPEK, S.A.B. de C.V. ( BMV:ALPEKA ), is not the largest company out there, but it saw significant share price movement...
分析記事 • Aug 30We Think ALPEK. de (BMV:ALPEKA) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Buying Opportunity • Aug 05Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 2.1%. The fair value is estimated to be Mex$34.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to decline by 4.4% per annum. Earnings is also forecast to decline by 37% per annum over the same time period.
